LGND Profile
Ligand Pharmaceuticals Incorporated, headquartered in San Diego, California, is a leading biopharmaceutical company dedicated to advancing medical treatment through innovative technologies and partnerships. Established in 1987, Ligand focuses on developing and acquiring cutting-edge technologies that facilitate pharmaceutical companies in their quest to discover and develop medicines globally.
Ligand's robust portfolio includes a diverse array of commercial programs and therapeutic solutions. Key products such as Kyprolis, Evomela, and Rylaze are pivotal in treating conditions like multiple myeloma and acute lymphoblastic leukemia. The company also offers breakthrough treatments like Veklury for COVID-19, Teriparatide injection for osteoporosis, and vaccines such as Vaxneuvance and Pneumosil, aimed at combatting pneumococcal diseases.
Moreover, Ligand Pharmaceuticals has developed captisol-enabled formulations including Zulresso for postpartum depression and Noxafil-IV for fungal infections, showcasing its commitment to addressing critical medical needs. The company's comprehensive product line extends to Duavee for postmenopausal osteoporosis, Aziyo's portfolio for pericardial repair, and various treatments for autoimmune diseases, cancer, and hypertension.
In addition to its proprietary products, Ligand collaborates extensively through partner and licensed programs across clinical development stages. These initiatives target a wide spectrum of health challenges such as cancer, seizure disorders, diabetes, cardiovascular ailments, and liver and kidney diseases. Through its innovative approach and strategic alliances, Ligand Pharmaceuticals continues to pioneer advancements in biopharmaceuticals, enhancing healthcare outcomes worldwide.
|
